Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-4-26
pubmed:abstractText
To model inflammatory bowel disease, we assessed infection with Helicobacter hepaticus 3B1 (ATCC 51449) and a potential probiotic Lactobacillus reuteri (ATCC PTA-6475) in gnotobiotic B6.129P2-IL-10(tm1Cgn) (IL-10(-/-) ) mice. No typhlocolitis developed in germ-free controls (n=21) or in L. reuteri (n=8) or H. hepaticus (n=18) mono-associated mice for 20 weeks post-infection. As positive controls, three specific pathogen-free IL-10(-/-) mice dosed with H. hepaticus developed severe typhlocolitis within 11 weeks. Because L. reuteri PTA-6475 has anti-inflammatory properties in vitro, it was unexpected to observe significant typhlocolitis (P<0·0001) in mice that had been infected with L. reuteri followed in 1 week by H. hepaticus (n=16). The H. hepaticus colonization was not affected through 20 weeks post-infection but L. reuteri colonization was lower in co-infected compared with L. reuteri mono-associated mice at 8-11 weeks post-infection (P<0·05). Typhlocolitis was associated with an increased T helper type 1 serum IgG2c response to H. hepaticus in co-infected mice compared with H. hepaticus mono-associated mice (P<0·005) and similarly, mRNA expression in caecal-colonic tissue was elevated at least twofold for chemokine ligands and pro-inflammatory interleukin-1? (IL-1?), IL-1?, IL-12 receptor, tumour necrosis factor-? and inducible nitric oxide synthase. Anti-inflammatory transforming growth factor-?, lactotransferrin, peptidoglycan recognition proteins, Toll-like receptors 4, 6, 8 and particularly 9 gene expression, were also elevated only in co-infected mice (P<0·05). These data support that the development of typhlocolitis in H. hepaticus-infected IL-10(-/-) mice required co-colonization with other microbiota and in this study, required only L. reuteri. Although the effects other microbiota may have on H. hepaticus virulence properties remain speculative, further investigations using this gnotobiotic model are now possible.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1365-2567
pubmed:author
pubmed:copyrightInfo
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.
pubmed:issnType
Electronic
pubmed:volume
133
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
165-78
pubmed:dateRevised
2011-8-1
pubmed:meshHeading
pubmed-meshheading:21426337-Adaptive Immunity, pubmed-meshheading:21426337-Animals, pubmed-meshheading:21426337-B-Lymphocytes, pubmed-meshheading:21426337-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:21426337-Germ-Free Life, pubmed-meshheading:21426337-Helicobacter Infections, pubmed-meshheading:21426337-Helicobacter hepaticus, pubmed-meshheading:21426337-Immunity, Innate, pubmed-meshheading:21426337-Immunoglobulin A, pubmed-meshheading:21426337-Immunoglobulin G, pubmed-meshheading:21426337-Immunohistochemistry, pubmed-meshheading:21426337-Inflammatory Bowel Diseases, pubmed-meshheading:21426337-Interleukin-10, pubmed-meshheading:21426337-Lactobacillus reuteri, pubmed-meshheading:21426337-Mice, pubmed-meshheading:21426337-Mice, Knockout, pubmed-meshheading:21426337-Polymerase Chain Reaction
pubmed:year
2011
pubmed:articleTitle
Lactobacillus reuteri promotes Helicobacter hepaticus-associated typhlocolitis in gnotobiotic B6.129P2-IL-10(tm1Cgn) (IL-10(-/-) ) mice.
pubmed:affiliation
Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA. mwhary@mit.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural